ANDREW NATHAN WILNER M.D.
Prescription History 1306804257
Psychiatry & Neurology - Neurology in Memphis, TN


Quality Rating: 75.06 out of 100 score

NPI Status: Active since May 02, 2006

Contact Information

880 MADISON AVE
MEMPHIS, TN
ZIP 38103
Phone: (901) 545-6969
Fax: (901) 545-4748

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for ANDREW NATHAN WILNER M.D., an active Neurology specialist practicing in Memphis, TN. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 69 documented patient claims. Among these therapy options, the most frequently utilized medication is Phenobarbital, which accounts for 28 claims alone.

Medication Index

No matching medications currently found on file.

Gabapentin

Generic Formulation: GabapentinSpecialty: Neurology
Provider Metrics Summary
Total Claims 18
30-Day Fills 20.3
Days Supply 610
TN State Average Benchmarks
Peer Average Claims131.0
Peer Average 30-Day Fills168.7
Peer Average Days Supply4,844
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 86.3% less volume than the regional standard for practitioners inside TN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $351.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.54

State Avg Cost Per Claim

$17.09

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Levetiracetam

Generic Formulation: LevetiracetamSpecialty: Neurology
Provider Metrics Summary
Total Claims 12
30-Day Fills 34.0
Days Supply 1,020
TN State Average Benchmarks
Peer Average Claims53.0
Peer Average 30-Day Fills81.0
Peer Average Days Supply2,171
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 77.4% less volume than the regional standard for practitioners inside TN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,362.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$113.54

State Avg Cost Per Claim

$37.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.

Therapeutic Applications

Levetiracetam is used to treat seizures (epilepsy). It belongs to a class of drugs known as anticonvulsants. Levetiracetam may decrease the number of seizures you have.

Phenobarbital

Generic Formulation: PhenobarbitalSpecialty: Neurology
Provider Metrics Summary
Total Claims 28
30-Day Fills 34.0
Days Supply 1,004
TN State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills24.5
Peer Average Days Supply664
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 33.3% more claims than the standard regional baseline profile for TN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $969.29 across this reporting matrix range.

Provider Avg Cost Per Claim

$34.62

State Avg Cost Per Claim

$36.47

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.

Therapeutic Applications

This medication is used alone or with other medications to control seizures. Controlling and reducing seizures lets you do more of your normal daily activities, reduces your risk of harm when you lose consciousness, and lessens your risk for a possibly life-threatening condition of frequent, repeated seizures. Phenobarbital belongs to a class of drugs known as barbiturate anticonvulsants/hypnotics. It works by controlling the abnormal electrical activity in the brain that occurs during a seizure. This medication is also used for a short time (usually no more than 2 weeks) to help calm you or help you sleep during periods of anxiety. It works by affecting certain parts of the brain to cause calming.

Phenytoin Sodium Extended

Generic Formulation: Phenytoin Sodium ExtendedSpecialty: Neurology
Provider Metrics Summary
Total Claims 11
30-Day Fills 25.8
Days Supply 774
TN State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills35.6
Peer Average Days Supply938
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.0% less volume than the regional standard for practitioners inside TN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $793.49 across this reporting matrix range.

Provider Avg Cost Per Claim

$72.14

State Avg Cost Per Claim

$37.43

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Phenytoin is used to prevent and control seizures (also called an anticonvulsant or antiepileptic drug). It works by reducing the spread of seizure activity in the brain.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like ANDREW NATHAN WILNER M.D. provides transparency into local medical care patterns within Memphis, TN.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Neurology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.